Navigation Links
TRITON-TIMI 38 Stent Analysis Favors Prasugrel
Date:3/29/2008

Regardless of stent timing and type, prasugrel bests clopidogrel

CHICAGO, March 29 /PRNewswire/ -- Prasugrel has been shown to block platelet activity in patients with acute coronary syndromes (ACS) more effectively than clopidogrel, and to cut by more than half the risk of thrombosis, or blood clotting, inside the coronary stent. Now a new analysis of data from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel (TRITON-TIMI 38) reveals that the investigational drug maintains its edge over clopidogrel regardless of the type of stent, the amount of time since the stenting procedure, or the way stent thrombosis is defined.

The results of the TRITON-TIMI 38 analysis are being reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC). The study will be simultaneously published online in The Lancet.

For the main TRITON-TIMI 38 study, researchers recruited 13,608 patients with ACS who needed stenting from 707 medical centers in 30 countries. Patients were randomly assigned to anti-platelet therapy consisting of either a 300-mg loading dose of clopidogrel before the procedure, followed by a maintenance dose of 75 mg daily for one year, or to a loading dose of 60 mg of prasugrel, followed by 10 mg daily for one year. Both medications prevent unwanted blood clotting by inhibiting the ability of platelets to clump together.

Stephen D. Wiviott, MD, Brigham and Women's Hospital, Boston, led the new stent analysis. Of the 12,844 patients who ultimately were treated with at least one coronary stent, 6,461 patients received only bare-metal stents (BMS), and 5,743 patients r
'/>"/>

SOURCE SCAI-ACCi2
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine technology :

1. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
2. Study Finds Repeated Episodes of Stent Thrombosis Common
3. Stenting Techniques Vie in Branchpoint Lesions
4. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
5. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
6. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
7. MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
8. Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
11. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced ... the addition of Lt. Gen. Ronald R. Blanck, DO, ... Blanck & Associates, a federal health services consulting firm ... company board now has nine members. ,, Dr. Blanck ... officer and battalion surgeon in Vietnam. He retired 32 ...
(Date:12/14/2009)... Watson Pharmaceuticals, Inc. (NYSE: WPI ) ... to help maintain the bone health of prostate ... therapy (ADT). Nearly two million men are ... that, while highly effective and considered the "gold ... man,s risk for osteoporosis. ,, As part of ...
(Date:12/14/2009)... DOVER, Del., Dec. 14 Ohr Pharmaceutical Inc. ... selected Allen & Caron Inc, headquartered in Irvine, ... London, as its agency for investor relations and ... stage biotechnology company focused on developing advanced drugs ... pipeline compounds with potentially large, global markets: OHR/AVR118 ...
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Expands Board of Directors 2Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 2Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 3Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 4Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 5Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 2Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 3SPECT provides high quality images of small tumors 48912 1Pregnant women at high risk of complications from H1N1 influenza 48908 1Tata Consultancy Services Launches New Business Intelligence Solution for Hospitals and Healthcare Providers 48904 1Tata Consultancy Services Launches New Business Intelligence Solution for Hospitals and Healthcare Providers 48904 2Tata Consultancy Services Launches New Business Intelligence Solution for Hospitals and Healthcare Providers 48904 3Tata Consultancy Services Launches New Business Intelligence Solution for Hospitals and Healthcare Providers 48904 4
... Israel, February 4 Oramed,Pharmaceuticals, Inc. (OTCBB: ORMP.OB), ... that it has concluded a proof of concept,study ... its,proprietary technology. Eight healthy volunteers came for two ... The insulin suppositories showed rapid insulin absorption ...
... PDUFA Date for Cinryze for Acute HAE Indication is June ... ViroPharma Incorporated (Nasdaq: VPHM ) today announced ... priority review for Cinryze C1 Inhibitor (human) as a treatment ... Biologics License Application (sBLA), submitted to the FDA on December ...
Other Medicine Technology:Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository 2FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE) 2FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE) 3FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE) 4FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE) 5FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE) 6
(Date:12/14/2009)... UC San Diego School of Medicine and Osaka University ... prevent liver damage, including inflammation, fibrosis and cancer. The ... protein, TAK1, works could lead to new insights into ... "TAK1 appears to be a master regulator of liver ... and Dean of the UC San Diego School of ...
(Date:12/14/2009)... cites lower rates for meth and smoking, but ... 14 (HealthDay News) -- Fewer teenagers are using ... and abuse of prescription drugs remains high, U.S. ... that newer drugs, such as the hallucinogenic salvia ... intended for treatment of attention-deficit hyperactivity disorder (ADHD), ...
(Date:12/14/2009)... -- Concetta F. Conkling of Moraga, CA, retired Senior ... been elected Chair of the Board of Trustees of ... nearly 90-year-old organization to which Helen Keller devoted more ... York with offices in San Francisco, Dallas, ... dedicated to expanding possibilities for people with vision loss. ...
(Date:12/14/2009)... women,s hospital -- located within the C.S. Mott Children,s ... Jane Von Voigtlander ,, ANN ARBOR, Mich., Dec. ... has received a $15 million gift from the Ted ... made to the Health System for women,s health. It ... ,, The gift is being announced today in advance ...
(Date:12/14/2009)... the December issue of Mayo Clinic Proceedings , ... This retrospective study is the largest ever conducted in ... a serious disorder that disrupts the body,s normal production ... the bone marrow, leading to severe anemia, weakness, fatigue ... "In the past 20 years, management of primary myelofibrosis ...
Breaking Medicine News(10 mins):Health News:Scientists uncover protective mechanism against liver cancer 2Health News:Marijuana Use No Longer Dropping Among U.S. Teens 2Health News:Marijuana Use No Longer Dropping Among U.S. Teens 3Health News:Marijuana Use No Longer Dropping Among U.S. Teens 4Health News:The American Foundation for the Blind Welcomes New Board Chair, Concetta F. Conkling 2Health News:University of Michigan Health System Receives $15 Million Gift, The Largest Ever for Women's Health 2Health News:University of Michigan Health System Receives $15 Million Gift, The Largest Ever for Women's Health 3Health News:University of Michigan Health System Receives $15 Million Gift, The Largest Ever for Women's Health 4Health News:University of Michigan Health System Receives $15 Million Gift, The Largest Ever for Women's Health 5
... of Dr. Michael McCarty, is now offering full service ... answer for those who need dental work and yet ... made it safe and comfortable for people to have ... a painful experience. Dr. Michael McCarty from Austin Smiles ...
... at the Stanford University School of ,Medicine have found ... of individual proteins in cells and living mammals, providing ... precisely than ever ,before the functions of different ... speed the development of therapies ,in which cancer-fighting proteins ...
... Over-55 bettors more likely to ask casinos to bar them, ... 28 (HealthDay News) -- Older problem gamblers who ask to ... likely than younger gambling addicts to do so because they,re ... to a new study. , The study included 1,601 ...
... Institutes of Health has awarded iCRco partner Vixar a Phase I SBIR ... images in computed radiography systems. Vixar is developing the new technology ... evaluate the potential of the technology for the digital x-ray imaging market. ... ...
... Sept. 27 Lung Cancer Alliance,President and CEO Laurie ... at Lung Cancer Alliance, our Board, our advocates and ... sympathy,to the wife and family of Paul Newman., ... and film, loved by,audiences around the world. He and ...
... surge in allergy and asthma problems after Hurricane Ike and provides ... ... Houston, TX (PRWEB) September 24, 2008--Although Hurricane Ike has already ... of this devastating hurricane has yet to be determined. It ...
Other Medicine News:Health News:Austin Dentistry Clinic Now Offers Certified Full Service Sedation Dentistry -- All Gain, No Pain 2Health News:New way to control protein activity could lead to cancer therapies 2Health News:New way to control protein activity could lead to cancer therapies 3Health News:Older Problem Gamblers Face Increased Suicide Risk 2Health News:NIH Awards a Phase I Small Business Innovative Research Grant on "Novel Laser Scanning Technology for Computed Radiography" to VIXAR and iCRco 2Health News:A Statement from Lung Cancer Alliance on the Death of Paul Newman 2Health News:Sudden Rise in Allergies and Asthma After Hurricane Ike 2Health News:Sudden Rise in Allergies and Asthma After Hurricane Ike 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: